The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review
Open Access
- 26 August 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Advances in Therapy
- Vol. 27 (10), 714-730
- https://doi.org/10.1007/s12325-010-0063-0
Abstract
Opioid-induced constipation (OIC) is associated with negative impact of opioid analgesics on opioid receptors located in the gut wall. Until recently, OIC was treated symptomatically only, with different laxatives which did not target the pathophysiology of OIC. Recently, several opioid receptor antagonists have been introduced in the treatment of OIC. Methylnaltrexone (MNTX) is a peripheral mu-opioid receptor antagonist for subcutaneous administration, which does not evoke symptoms of opioid abstinence. MNTX is indicated for patients with OIC who are not amenable to therapy with oral laxatives. In clinical trials, the effectiveness of MNTX assessed as its ability to induce spontaneous bowel movement, is 50%–60% of treated patients; MNTX demonstrates significant superiority over placebo. Another product is combination of oral formulation of prolonged release oxycodone and prolonged release naloxone (PR oxycodone/PR naloxone), indicated for patients who require opioid administration for chronic pain and have already developed OIC, and for those who need opioid therapy and take the drug to prevent OIC. Naloxone administered orally displays local, antagonist effects on opioid receptors in the gut wall, negligible systemic bioavailability, and significantly reduces the oxycodone constipating effect. PR oxycodone/PR naloxone has similar analgesic efficacy, but causes less constipation and less laxative consumption in comparison with patients treated with oxycodone alone. Both products are expensive, therefore their administration should be carefully considered. On the other hand, uncontrolled OIC and the necessity to perform rectal invasive procedures (enema, manual evacuation) lead not only to increased health care costs, but most importantly, cause severe patient suffering.Keywords
This publication has 58 references indexed in Scilit:
- A randomised controlled trial with prolonged‐release oral oxycodone and naloxone to prevent and reverse opioid‐induced constipationEuropean journal of pain, 2009
- Meeting the Challenges of Opioid-Induced Constipation in Chronic Pain Management – A Novel ApproachPharmacology, 2008
- Diarrhea and Constipation: Supportive Oncology ManagementPublished by Springer Science and Business Media LLC ,2008
- The management of constipation in palliative care: clinical practice recommendationsPalliative Medicine, 2008
- Treatment of opioid-induced gut dysfunctionExpert Opinion on Investigational Drugs, 2007
- 656 OPIOID‐INDUCED CONSTIPATION — A FREQUENT AND DISTRESSING SIDE EFFECT IN DAILY PRACTICE AFFECTING ORAL AND TRANSDERMAL OPIOID APPLICATIONSEuropean Journal of Pain Supplements, 2006
- Validation of the PAC‐SYM questionnaire for opioid‐induced constipation in patients with chronic low back painEuropean journal of pain, 2006
- The opioid bowel syndrome: A review of pathophysiology and treatmentJournal of Opioid Management, 2005
- Incidence, Prevalence, and Management of Opioid Bowel DysfunctionThe American Journal of Surgery, 2001
- The relationship between opioid use and laxative use in terminally ill cancer patientsPalliative Medicine, 1998